Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company that develops innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company focuses on genetically engineering commensal skin bacteria, primarily Staphylococcus epidermidis, to deliver therapeutic proteins and living organisms into deeper skin layers. Its product candidate pipeline includes ATR-12 for treating Netherton syndrome, ATR-04 for papulopustular rash caused by epidermal growth factor receptor inhibitor cancer therapies, and ATR-01 for ichthyosis vulgaris. Azitra serves patients suffering from rare, chronic, and treatment-induced dermatologic conditions.

The company operates a proprietary microbial library containing approximately 1,500 unique bacterial strains and over 60 distinct bacterial species. Azitra has not commenced commercial operations and pursues partnerships and licensing agreements with academic and research institutions across the United States. Azitra was incorporated under Delaware law, and the provided text does not disclose its specific headquarters location.

Summary of the business section of Azitra's latest annual report, written by StockData.

“As of the date of this report, we have 13 employees and full-time consultants, including our executive officers, providing management and financial services, and general administrative responsibilities.”